tiprankstipranks
Trending News
More News >
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
US Market

Intellia Therapeutics (NTLA) Stock Forecast & Price Target

Compare
3,619 Followers
See the Price Targets and Ratings of:

NTLA Analyst Ratings

Moderate Buy
22Ratings
Moderate Buy
17 Buy
4 Hold
1 Sell
Based on 22 analysts giving stock ratings to
Intellia
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NTLA Stock 12 Month Forecast

Average Price Target

$29.65
▲(176.33%Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $29.65 with a high forecast of $65.00 and a low forecast of $7.00. The average price target represents a 176.33% change from the last price of $10.73.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","66":"$66","20.25":"$20.3","35.5":"$35.5","50.75":"$50.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,20.25,35.5,50.75,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.16,11.60923076923077,16.05846153846154,20.50769230769231,24.95692307692308,29.40615384615385,33.85538461538462,38.30461538461539,42.753846153846155,47.20307692307692,51.6523076923077,56.10153846153847,60.550769230769234,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.16,8.89,10.620000000000001,12.35,14.08,15.81,17.54,19.27,21,22.73,24.46,26.19,27.919999999999998,{"y":29.65,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.16,7.147692307692308,7.135384615384615,7.1230769230769235,7.110769230769231,7.098461538461539,7.086153846153846,7.073846153846154,7.061538461538461,7.049230769230769,7.036923076923077,7.024615384615385,7.012307692307692,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.5,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.38,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.47,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.14,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.2,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.81,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.32,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$65.00Average Price Target$29.65Lowest Price Target$7.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on NTLA
TipRanks AITipRanks
Not Ranked
TipRanks
$10.5
Hold
-2.14%
Downside
Reiterated
07/02/25
Intellia Therapeutics' overall score reflects significant clinical advancements and positive corporate events, tempered by financial instability and valuation challenges. The technical analysis indicates potential bullish momentum, adding moderate strength to the overall assessment.
Bernstein
$14
Buy
30.48%
Upside
Reiterated
06/19/25
Bernstein Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)
Citizens JMP Analyst forecast on NTLA
Silvan TuerkcanCitizens JMP
Citizens JMP
Hold
Reiterated
06/17/25
Citizens JMP Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)
JonesTrading
$25
Buy
132.99%
Upside
Reiterated
06/16/25
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (NYSE: ELAN), Kura Oncology (NASDAQ: KURA) and Intellia Therapeutics (NASDAQ: NTLA)
Wells Fargo Analyst forecast on NTLA
Yanan ZhuWells Fargo
Wells Fargo
$50
Buy
365.98%
Upside
Reiterated
06/16/25
Intellia Therapeutics: Expert Confidence in Addressing Liver Enzyme Concerns Supports Buy Rating
H.C. Wainwright Analyst forecast on NTLA
Mitchell KapoorH.C. Wainwright
H.C. Wainwright
$30
Buy
179.59%
Upside
Reiterated
06/16/25
Intellia Therapeutics' NTLA-2002 Shows Promising Efficacy and Safety in HAE Treatment, Supporting Buy Rating
Wedbush Analyst forecast on NTLA
Unknown AnalystWedbush
Not Ranked
Wedbush
$7
Hold
-34.76%
Downside
Assigned
06/16/25
Wedbush Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)
Leerink Partners Analyst forecast on NTLA
Mani ForooharLeerink Partners
Leerink Partners
Buy
Reiterated
06/15/25
Promising Phase 1 Results and High Interest in Phase 3 Trial Boost Buy Rating for Intellia Therapeutics
BMO Capital Analyst forecast on NTLA
Kostas BiliourisBMO Capital
BMO Capital
$20
Buy
86.39%
Upside
Reiterated
06/15/25
Intellia Therapeutics' Lonvo-z Shows Promising Efficacy and Safety, Supporting Buy Rating
Citi
$8.31$10
Hold
-6.80%
Downside
Reiterated
06/13/25
Intellia's Lonvo-z: Promising Phase 1 Results Amid Market Competitiveness and Safety Concerns
Canaccord Genuity Analyst forecast on NTLA
Whitney IjemCanaccord Genuity
Canaccord Genuity
$74$54
Buy
403.26%
Upside
Reiterated
06/02/25
Intellia Therapeutics price target lowered to $54 from $74 at CanaccordIntellia Therapeutics price target lowered to $54 from $74 at Canaccord
Truist Financial Analyst forecast on NTLA
Joon LeeTruist Financial
Truist Financial
Buy
Reiterated
05/29/25
Truist Financial Remains a Buy on Intellia Therapeutics (NTLA)
Evercore ISI Analyst forecast on NTLA
Liisa BaykoEvercore ISI
Evercore ISI
$48
Buy
347.34%
Upside
Reiterated
05/29/25
Evercore ISI Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
Goldman Sachs Analyst forecast on NTLA
Salveen RichterGoldman Sachs
Goldman Sachs
$8
Sell
-25.44%
Downside
Reiterated
05/29/25
Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating
William Blair Analyst forecast on NTLA
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
05/29/25
Positive Outlook for Intellia Therapeutics Despite Safety Concerns in MAGNITUDE Trial
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on NTLA
TipRanks AITipRanks
Not Ranked
TipRanks
$10.5
Hold
-2.14%
Downside
Reiterated
07/02/25
Intellia Therapeutics' overall score reflects significant clinical advancements and positive corporate events, tempered by financial instability and valuation challenges. The technical analysis indicates potential bullish momentum, adding moderate strength to the overall assessment.
Bernstein
$14
Buy
30.48%
Upside
Reiterated
06/19/25
Bernstein Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)
Citizens JMP Analyst forecast on NTLA
Silvan TuerkcanCitizens JMP
Citizens JMP
Hold
Reiterated
06/17/25
Citizens JMP Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)
JonesTrading
$25
Buy
132.99%
Upside
Reiterated
06/16/25
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (NYSE: ELAN), Kura Oncology (NASDAQ: KURA) and Intellia Therapeutics (NASDAQ: NTLA)
Wells Fargo Analyst forecast on NTLA
Yanan ZhuWells Fargo
Wells Fargo
$50
Buy
365.98%
Upside
Reiterated
06/16/25
Intellia Therapeutics: Expert Confidence in Addressing Liver Enzyme Concerns Supports Buy Rating
H.C. Wainwright Analyst forecast on NTLA
Mitchell KapoorH.C. Wainwright
H.C. Wainwright
$30
Buy
179.59%
Upside
Reiterated
06/16/25
Intellia Therapeutics' NTLA-2002 Shows Promising Efficacy and Safety in HAE Treatment, Supporting Buy Rating
Wedbush Analyst forecast on NTLA
Unknown AnalystWedbush
Not Ranked
Wedbush
$7
Hold
-34.76%
Downside
Assigned
06/16/25
Wedbush Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)
Leerink Partners Analyst forecast on NTLA
Mani ForooharLeerink Partners
Leerink Partners
Buy
Reiterated
06/15/25
Promising Phase 1 Results and High Interest in Phase 3 Trial Boost Buy Rating for Intellia Therapeutics
BMO Capital Analyst forecast on NTLA
Kostas BiliourisBMO Capital
BMO Capital
$20
Buy
86.39%
Upside
Reiterated
06/15/25
Intellia Therapeutics' Lonvo-z Shows Promising Efficacy and Safety, Supporting Buy Rating
Citi
$8.31$10
Hold
-6.80%
Downside
Reiterated
06/13/25
Intellia's Lonvo-z: Promising Phase 1 Results Amid Market Competitiveness and Safety Concerns
Canaccord Genuity Analyst forecast on NTLA
Whitney IjemCanaccord Genuity
Canaccord Genuity
$74$54
Buy
403.26%
Upside
Reiterated
06/02/25
Intellia Therapeutics price target lowered to $54 from $74 at CanaccordIntellia Therapeutics price target lowered to $54 from $74 at Canaccord
Truist Financial Analyst forecast on NTLA
Joon LeeTruist Financial
Truist Financial
Buy
Reiterated
05/29/25
Truist Financial Remains a Buy on Intellia Therapeutics (NTLA)
Evercore ISI Analyst forecast on NTLA
Liisa BaykoEvercore ISI
Evercore ISI
$48
Buy
347.34%
Upside
Reiterated
05/29/25
Evercore ISI Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
Goldman Sachs Analyst forecast on NTLA
Salveen RichterGoldman Sachs
Goldman Sachs
$8
Sell
-25.44%
Downside
Reiterated
05/29/25
Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating
William Blair Analyst forecast on NTLA
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
05/29/25
Positive Outlook for Intellia Therapeutics Despite Safety Concerns in MAGNITUDE Trial
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Intellia Therapeutics

1 Month
xxx
Success Rate
15/37 ratings generated profit
41%
Average Return
+3.19%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 40.54% of your transactions generating a profit, with an average return of +3.19% per trade.
3 Months
xxx
Success Rate
14/37 ratings generated profit
38%
Average Return
+12.72%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 37.84% of your transactions generating a profit, with an average return of +12.72% per trade.
1 Year
Geulah LivshitsChardan Capital
Success Rate
14/37 ratings generated profit
38%
Average Return
+89.80%
reiterated a buy rating 8 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 37.84% of your transactions generating a profit, with an average return of +89.80% per trade.
2 Years
xxx
Success Rate
13/37 ratings generated profit
35%
Average Return
+101.94%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 35.14% of your transactions generating a profit, with an average return of +101.94% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NTLA Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
41
24
14
24
27
Buy
5
3
2
9
8
Hold
11
6
4
6
9
Sell
1
1
1
1
1
Strong Sell
0
0
0
0
0
total
58
34
21
40
45
In the current month, NTLA has received 35 Buy Ratings, 9 Hold Ratings, and 1 Sell Ratings. NTLA average Analyst price target in the past 3 months is 29.65.
Each month's total comprises the sum of three months' worth of ratings.

NTLA Financial Forecast

NTLA Earnings Forecast

Next quarter’s earnings estimate for NTLA is -$1.02 with a range of -$1.30 to -$0.61. The previous quarter’s EPS was -$1.10. NTLA beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year NTLA has Outperformed its overall industry.
Next quarter’s earnings estimate for NTLA is -$1.02 with a range of -$1.30 to -$0.61. The previous quarter’s EPS was -$1.10. NTLA beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year NTLA has Outperformed its overall industry.

NTLA Sales Forecast

Next quarter’s sales forecast for NTLA is $11.99M with a range of $0.00 to $50.00M. The previous quarter’s sales results were $16.63M. NTLA beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year NTLA has Outperformed its overall industry.
Next quarter’s sales forecast for NTLA is $11.99M with a range of $0.00 to $50.00M. The previous quarter’s sales results were $16.63M. NTLA beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year NTLA has Outperformed its overall industry.

NTLA Stock Forecast FAQ

What is NTLA’s average 12-month price target, according to analysts?
Based on analyst ratings, Intellia Therapeutics’s 12-month average price target is 29.65.
    What is NTLA’s upside potential, based on the analysts’ average price target?
    Intellia Therapeutics has 176.33% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NTLA a Buy, Sell or Hold?
          Intellia Therapeutics has a consensus rating of Moderate Buy which is based on 17 buy ratings, 4 hold ratings and 1 sell ratings.
            What is Intellia Therapeutics’s price target?
            The average price target for Intellia Therapeutics is 29.65. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $65.00 ,the lowest forecast is $7.00. The average price target represents 176.33% Increase from the current price of $10.73.
              What do analysts say about Intellia Therapeutics?
              Intellia Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of NTLA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis